Pasar al contenido principal

CANALES KV COMO DIANAS FARMACOLOGICAS EN LA HIPERTENSION ARTERIAL PULMONAR Y DISFUNCION ERECTIL

PID2020-117939RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD COMPLUTENSE DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Docta Complutense
Publicación Artículo científico (JournalArticle)

Expression and activity of the umami taste receptor (TAS1R1/TAS1R3) in rat corpus cavernosum

  • Navarro Dorado, Jorge
  • Juan-José Gibello, Laura
  • López-Oliva Muñoz, María Elvira
  • Martínez Sainz, María Del Pilar
  • Hernández Martín, Marina
  • Climent Flórez, Belén
  • Agis Torres, Ángel
  • Recio Visedo, María Paz
  • Barahona Gomáriz, María Victoria
  • Benedito Castellote, Sara
  • Fernandes, Vítor S.
  • Hernández Rodríguez, Medardo Vicente
The activation of umami taste receptors (TAS1R1/TAS1R3) promotes smooth muscle (SM) relaxation in the mouse stomach. The nitric oxide (NO)/cGMP signaling pathway is crucial for penile erection. Phosphodiesterase type 5 (PDE5) inhibitors, which specifically target cGMP, are the primary treatment for erectile dysfunction (ED). However, these drugs are ineffective in a significant number of patients, highlighting the need for alternative pharmacological targets for ED. Since umami taste receptors regulate SM contractility, this study investigates the role of TAS1R1/TAS1R3 in rat erectile tissue. We performed immunohistochemistry on the corpus cavernosum (CC) and dorsal penile artery (DPA) to detect TAS1R1/TAS1R3 expression. Isometric force recordings for the TAS1R1/TAS1R3 agonist monosodium glutamate (MSG), the NO donor SNAP, the hydrogen sulfide (H2S) donor GYY 4137, and electrical field stimulation (EFS) and measured endogenous H2S production. Immunohistochemistry revealed strong TAS1R1/TAS1R3 expression in nerve fibers of the CC and in the endothelium of the DPA, with limited expression in SM. In the CC, MSG enhanced relaxations induced by EFS, SNAP, and GYY 4137, and increased H2S production, which was sensitive to NO and H2S synthase inhibitors. MSG-induced relaxation was reduced by inhibition of neuronal voltage-gated calcium channels. In the DPA, MSG induced relaxation which was reduced by mechanical removal of the endothelium. These findings indicate significant neuronal and endothelial expression of TAS1R1/TAS1R3 in the CC and DPA, where MSG promotes SM relaxation. In the CC, MSG enhances nerve-mediated relaxation induced by NO and H2S and stimulates H2S production, suggesting TAS1R1/TAS1R3 as a potential therapeutic target for ED
Docta Complutense
Publicación Artículo científico (JournalArticle)

Functional expression of inwardly rectifying and ATP-sensitive potassium channels in human pulmonary artery smooth muscle and endothelial cells.

  • Barreira, Bianca
  • Morales Cano, Daniel
  • Moreno Gutiérrez, Laura
  • de Olaiz, Beatriz
  • Adão, Rui
  • Cogolludo Torralba, Ángel Luis
  • Pérez Vizcaíno, Francisco
  • Sancho González, María
The resting membrane potential (V) of vascular cells is a key determinant of arterial tone, integrating multiple ionic conductances to control smooth muscle contractility and endothelial signalling. In the human pulmonary circulation, the specific K channels responsible for setting the V of smooth muscle cells (SMCs) and endothelial cells (ECs) remain incompletely defined. This study investigated whether inwardly rectifying (Kir2) and ATP-sensitive (K) K channels are functionally expressed in native human pulmonary artery (PA) SMCs and ECs and assessed their contribution to vascular tone. Combining patch-clamp electrophysiology, immunofluorescence and wire myography, we evaluated channel expression and function in freshly isolated PASMCs and PAECs, and intact PAs. Kir2 channels were identified by Ba-sensitive inward currents with a characteristic rectification profile, supported by immunolabelling of Kir2.1 and Kir2.2 subunits. Functionally, BaCl induced concentration-dependent contractions of PA rings and significantly attenuated acetylcholine-evoked, endothelium-dependent relaxation, revealing a tonic vasodilatory role for Kir2 channels. K currents, activated by pinacidil and blocked by glibenclamide and PNU-37883A, were also observed in PASMCs and PAECs, consistent with immunodetection of Kir6.1 and SUR2 subunits. In isolated PAs, pinacidil elicited concentration-dependent vasodilatation, which was significantly reduced by K channel blockade. Collectively, these findings demonstrate for the first time the functional presence of Kir2 and K channels in native human pulmonary vascular cells, and their modulatory role on V and arterial tone. These channels emerge as key electro-metabolic regulators of pulmonary vascular function and promising therapeutic targets in diseases characterized by V dysregulation, such as pulmonary arterial hypertension. KEY POINTS: Inwardly rectifying (Kir2) K channels are key regulators of the resting membrane potential (V) in different vascular cell types across multiple vascular beds, whereas ATP-sensitive (K) K channels detect changes in the metabolic state of vascular cells and translate these changes into V modulation. Despite their well-established physiological relevance, a comprehensive characterization of Kir2 and K channels in freshly isolated human pulmonary vascular cells - particularly within the endothelium - remains lacking. Our study provides compelling evidence for the functional expression of Kir2 and K channels in native human pulmonary arterial smooth muscle and endothelial cells, demonstrating their contribution to V regulation and pulmonary vascular tone at rest and in response to specific stimuli.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Vitamin D as an add-on therapy to phosphodiesterase-5 inhibitor in experimental pulmonary arterial hypertension

  • Adão, Rui
  • Barreira, Bianca
  • Paternoster, Elena
  • Morales-Cano, Daniel
  • Olivencia, Miguel A.
  • Quintana-Villamandos, Begoña
  • Rodríguez Chiaradia, Diego Agustín
  • Cogolludo, Angel
  • Perez-Vizcaino, Francisco
Severe vitamin D (vitD) deficiency is a very common condition in patients with pulmonary arterial hypertension (PAH), and it is a predictor of poor prognosis. There is emerging evidence suggesting a connection between the insufficient response to phosphodiesterase-5 inhibitors (PDE5i) and vitD deficiency in patients with PAH. In the present translational study, vitD deficiency was induced in Wistar rats by exposure to vitD-free diet for 5 wk and followed by Su5416 administration and hypoxia (10%) for 3 wk, a standard experimental model of PAH. Then, rats were randomized to either 1) the PDE5i tadalafil and continuing vitD-free diet or 2) tadalafil plus a single dose of vitD and standard diet for 4 wk. VitD supplementation improved exercise capacity and right ventricular function and decreased systolic right ventricular pressure, right atrial hypertrophy, right ventricular hypertrophy, and pulmonary arterial remodeling. VitD improved the ex vivo endothelium-dependent response to acetylcholine, indicating an improvement in NO bioavailability, which also resulted in an acute ex vivo response to sildenafil. Thus, the restoration of vitD, by rescuing endothelial function and PDE5i effectiveness, significantly improved the histological, hemodynamic, and functional features of rats with PAH. VitD may be especially beneficial for PDE5i-treated patients with PAH. NEW & NOTEWORTHY Severe vitamin D deficiency is very prevalent in patients with pulmonary arterial hypertension. We show that addition of vitamin D to the standard PDE5 inhibitor tadalafil increases its therapeutic efficacy in pulmonary hypertensive rats that were deficient in vitamin D., This study was supported by grants from Ministerio de Economía y Competitividad (PID2019-107363RB-I00 and PID2020-117939RB-I00), Fundación Contra la Hipertensión Pulmonar (FCHP, Empathy study) and Sociedad Española de Neumología y Cirugía Torácica (SEPAR, 1204/2022). R.A. is funded by the EC Horizon 2020 Marie Skłodowska-Curie grant (No. 847635), and acknowledges Fundação para a Ciência e a Technologia (FCT) under the auspices of the project RELAX-2-PAH (2022.08921.PTDC; https://doi.org/10.54499/2022.08921.PTDC). M.A.O. is funded by Universidad Complutense/Banco Santander CT63/19-CT64/19.
Investigo. Repositorio Institucional de la Universidade de Vigo
Publicación Artículo científico (JournalArticle)

Novel loss-of-function KCNA5 variants in pulmonary arterial hypertension

  • Vera-Zambrano, Alba
  • Lago Docampo, Mauro
  • Gallego, Natalia
  • Franco-Gonzalez, Juan Felipe
  • Morales-Cano, Daniel
  • Cruz Utrilla, Alejandro
  • Villegas-Esguevillas, Marta
  • Fernández-Malavé, Edgar
  • Escribano Subías, Pilar
  • Tenorio Castaño, Jair Antonio
  • Perez-Vizcaino, Francisco
  • Valverde Pérez, Diana
  • Mourin Gonzalez, Maria Teresa
  • Cogolludo Agustin, Miguel Angel
Reduced expression and/or activity of Kv1.5 channels (encoded by KCNA5) is a common hallmark in human or experimental pulmonary arterial hypertension (PAH). Likewise, genetic variants in KCNA5 have been found in patients with PAH, but their functional consequences and potential impact on the disease are largely unknown. Herein, this study aimed to characterize the functional consequences of seven KCNA5 variants found in a cohort of patients with PAH. Potassium currents were recorded by patch-clamp technique in HEK293 cells transfected with wild-type or mutant Kv1.5 cDNA. Flow cytometry, Western blot, and confocal microscopy techniques were used for measuring protein expression and cell apoptosis in HEK293 and human pulmonary artery smooth muscle cells. KCNA5 variants (namely, Arg184Pro and Gly384Arg) found in patients with PAH resulted in a clear loss of potassium channel function as assessed by electrophysiological and molecular modeling analyses. The Arg184Pro variant also resulted in a pronounced reduction of Kv1.5 expression. Transfection with Arg184Pro or Gly384Arg variants decreased apoptosis of human pulmonary artery smooth muscle cells compared with the wild-type cells, demonstrating that KCNA5 dysfunction in both variants affects cell viability. Thus, in addition to affecting channel activity, both variants were associated with impaired apoptosis, a crucial process linked to the disease. The estimated prevalence of dysfunctional KCNA5 variants in the PAH population analyzed was around 1%. The data indicate that some KCNA5 variants found in patients with PAH have critical consequences for channel function, supporting the idea that KCNA5 pathogenic variants may be a causative or contributing factor for PAH., Comunidad de Madrid | Ref. B2017/BMD-3727, Instituto de Salud Carlos III | Ref. PI18/01233, Instituto de Salud Carlos III | Ref. PI21/01593, Agencia Estatal de Investigación | Ref. PID2020-117939RB-I00, Agencia Estatal de Investigación | Ref. PID2019-104366RB-C21, Agencia Estatal de Investigación | Ref. PID2019-107363RB-I00, Xunta de Galicia | Ref. ED481A-2018/304
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Novel loss of function KCNA5 variants in pulmonary arterial hypertension, Running title: Novel loss of function KCNA5 variants in PAH

  • Vera-Zambrano, Alba
  • Lago-Docampo, Mauro
  • Gallego, Natalia
  • Franco-Gonzalez, Juan Felipe
  • Morales-Cano, Daniel
  • Cruz-Utrilla, Alejandro
  • Villegas-Esguevillas, Marta
  • Fernández-Malavé, Edgar
  • Escribano-Subias, Pilar
  • Tenorio, Jair
  • Pérez-Vizcaíno, Francisco
  • Valverde, Diana
  • González, Teresa
  • SICPH investigators
  • Cogolludo, Angel
12 p.-7 fig., Reduced expression and/or activity of Kv1.5 channels (encoded by KCNA5) is a common hallmark in human or experimental pulmonary arterial hypertension (PAH). Likewise, genetic variants in KCNA5 have been found in PAH patients, but their functional consequences and potential impact on the disease are largely unknown. Herein, we aimed to characterize the functional consequences of 7 KCNA5 variants found in a cohort of PAH patients. Potassium currents were recorded by patch-clamp technique in HEK293 cells transfected with WT or mutant Kv1.5 cDNA. Flow cytometry, western blot and confocal microscopy techniques were used for measuring protein expression and cell apoptosis in HEK293 and human pulmonary artery smooth muscle cells (hPASMC). KCNA5 variants found in PAH patients (namely, p.Arg184Pro and p.Gly384Arg) resulted in a clear loss of potassium channel function as assessed by electrophysiological and molecular modelling analyses. The p.Arg184Pro variant also resulted in a pronounced reduction of Kv1.5 expression. Transfection with p.Arg184Pro or p.Gly384Arg variants decreased apoptosis of hPASMCs compared with the WT, demonstrating that KCNA5 dysfunction in both variants affects cell viability. Thus, in addition to affecting channel activity, both variants were associated with impaired apoptosis, a crucial process linked to the disease. The estimated prevalence of dysfunctional KCNA5 variants in the PAH population analyzed was around 1 %. Our data indicate that some KCNA5 variants found PAH patients have critical consequences for channel function supporting the idea that KCNA5 pathogenic variants may be a causative or contributing factor for PAH., This work was supported by Fundación Contra la Hipertensión Pulmonar (FCHP); Ministerio de Ciencia e Innovación [PID2020-117939RB-I00 to AC, PID2019-104366RB-C21 to TG, PID2019-107363RB-I00 to FPV]; Comunidad de Madrid [B2017/BMD-3727 to AC] and Instituto de Salud Carlos III [PI18/01233, PI21/01593] with funds from the European Union (Fondo Europeo de Desarrollo Regional FEDER); and by an annual grant by the FEDER foundation (Federación Española de Enfermedades Raras)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Vitamin D Receptor Deficiency Upregulates Pulmonary Artery Kv7 Channel Activity

  • Olivencia, Miguel A.
  • Villegas-Esguevillas, Marta
  • López Sancho, José María
  • Barreira, Bianca
  • Paternoster, Elena
  • Adão, Rui
  • Larriba, María Jesús
  • Cogolludo, Angel
  • Pérez-Vizcaíno, Francisco
Recent evidence suggests that vitamin D is involved in the development of pulmonary arterial hypertension (PAH). The aim of this study was to analyze the electrophysiological and contractile properties of pulmonary arteries (PAs) in vitamin D receptor knockout mice (Vdr−/−). PAs were dissected and mounted in a wire myograph. Potassium membrane currents were recorded in freshly isolated PA smooth muscle cells (PASMCs) using the conventional whole-cell configuration of the patch-clamp technique. Potential vitamin D response elements (VDREs) in Kv7 channels coding genes were studied, and their protein expression was analyzed. Vdr−/− mice did not show a pulmonary hypertensive phenotype, as neither right ventricular hypertrophy nor endothelial dysfunction was apparent. However, resistance PA from these mice exhibited increased response to retigabine, a Kv7 activator, compared to controls and heterozygous mice. Furthermore, the current sensitive to XE991, a Kv7 inhibitor, was also higher in PASMCs from knockout mice. A possible VDRE was found in the gene coding for KCNE4, the regulatory subunit of Kv7.4. Accordingly, Vdr−/− mice showed an increased expression of KCNE4 in the lungs, with no changes in Kv7.1 and Kv7.4. These results indicate that the absence of Vdr in mice, as occurred with vitamin D deficient rats, is not sufficient to induce PAH. However, the contribution of Kv7 channel currents to the regulation of PA tone is increased in Vdr−/− mice, resembling animals and humans suffering from PAH., The work in the authors’ laboratories is funded by the Agencia Estatal de Investigación (PID2019-104867RB-I00 and PID2020-117939RB-I00, PID/AEI/10.13039/501100011033), the Instituto de Salud Carlos III—Fondo Europeo de Desarrollo Regional (CIBERES/CB06/06/1084 and CIBERONC/CB16/12/00273), and the Fundación contra la hipertensión pulmonar (FCHP). M.J.L. belongs to the Spanish National Research Council (CSIC)’s Cancer Hub. M.A.O. is funded by Universidad Complutense/Banco Santander CT63/19-CT64/19. R.A. has received funding from the European Union’s Horizon 2020 research and innovation programme under Marie-Curie grant agreement Nº 847635., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Sigma-1 receptor modulation fine-tunes KV1.5 channels and impacts pulmonary vascular function

  • Vera-Zambrano, Alba
  • Baena-Nuevo, M.
  • Rinné, Susanne
  • Villegas-Esguevillas, Marta
  • Barreira, Bianca
  • Telli, Gokcen
  • Benito-Bueno, Ángela de
  • Blázquez, J. A.
  • Climent, Belén
  • Pérez-Vizcaíno, Francisco
  • Valenzuela, Carmen
  • Decher, Niels
  • González, Teresa
  • Cogolludo, Angel
KV1.5 channels are key players in the regulation of vascular tone and atrial excitability and their impairment is associated with cardiovascular diseases including pulmonary arterial hypertension (PAH) and atrial fibrillation (AF). Unfortunately, pharmacological strategies to improve KV1.5 channel function are missing. Herein, we aimed to study whether the chaperone sigma-1 receptor (S1R) is able to regulate these channels and represent a new strategy to enhance their function. By using different electrophysiological and molecular techniques in X. laevis oocytes and HEK293 cells, we demonstrate that S1R physically interacts with KV1.5 channels and regulate their expression and function. S1R induced a bimodal regulation of KV1.5 channel expression/activity, increasing it at low concentrations and decreasing it at high concentrations. Of note, S1R agonists (PRE084 and SKF10047) increased, whereas the S1R antagonist BD1047 decreased, KV1.5 expression and activity. Moreover, PRE084 markedly increased KV1.5 currents in pulmonary artery smooth muscle cells and attenuated vasoconstriction and proliferation in pulmonary arteries. We also show that both KV1.5 channels and S1R, at mRNA and protein levels, are clearly downregulated in samples from PAH and AF patients. Moreover, the expression of both genes showed a positive correlation. Finally, the ability of PRE084 to increase KV1.5 function was preserved under sustained hypoxic conditions, as an in vitro PAH model. Our study provides insight into the key role of S1R in modulating the expression and activity of KV1.5 channels and highlights the potential role of this chaperone as a novel pharmacological target for pathological conditions associated with KV1.5 channel dysfunction., This work was supported by Ministerio de Ciencia e Inovación [SAF2016-75021-R; PID2019-104366RB-C21 to C.V. and T.G., PID2020-117939RB-I00 to A.C., PID2019-107363RB-I00 to F.P.V.]; by CIBERCV, by Instituto de Salud Carlos III [CB/11/00222 to C.V.], by CSIC [PIE201820E104; 2019AEP148 to C.V.]. BES-2017-080184 (to A.B.-B.), funded by MCIN/AEI/ 10.13039/501100011033 and by “ESF Investing in your future” funded by Ministerio de Ciencia e Innovación. A.V.-Z., M.B.-N., A.B.-B. and M.V-E. was awarded with predoctoral fellowships: FPI-UAM, CSIC, FPI and FPU predoctoral contracts, respectively. A.V.-Z. was awarded with a Short-term fellowship from the European Molecular Biology Organization (EMBO)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Vitamin D as an add-on therapy to phosphodiesterase-5 inhibitor in experimental pulmonary arterial hypertension

  • Adão, Rui
  • Barreira, Bianca
  • Paternoster, Elena
  • Morales-Cano, Daniel
  • Olivencia, Miguel A.
  • Quintana-Villamandos, Begoña
  • Rodríguez Chiaradia, Diego Agustín
  • Cogolludo, Angel
  • Perez-Vizcaino, Francisco
Severe vitamin D (vitD) deficiency is a very common condition in patients with pulmonary arterial hypertension (PAH), and it is a predictor of poor prognosis. There is emerging evidence suggesting a connection between the insufficient response to phosphodiesterase-5 inhibitors (PDE5i) and vitD deficiency in patients with PAH. In the present translational study, vitD deficiency was induced in Wistar rats by exposure to vitD-free diet for 5 wk and followed by Su5416 administration and hypoxia (10%) for 3 wk, a standard experimental model of PAH. Then, rats were randomized to either 1) the PDE5i tadalafil and continuing vitD-free diet or 2) tadalafil plus a single dose of vitD and standard diet for 4 wk. VitD supplementation improved exercise capacity and right ventricular function and decreased systolic right ventricular pressure, right atrial hypertrophy, right ventricular hypertrophy, and pulmonary arterial remodeling. VitD improved the ex vivo endothelium-dependent response to acetylcholine, indicating an improvement in NO bioavailability, which also resulted in an acute ex vivo response to sildenafil. Thus, the restoration of vitD, by rescuing endothelial function and PDE5i effectiveness, significantly improved the histological, hemodynamic, and functional features of rats with PAH. VitD may be especially beneficial for PDE5i-treated patients with PAH. NEW & NOTEWORTHY Severe vitamin D deficiency is very prevalent in patients with pulmonary arterial hypertension. We show that addition of vitamin D to the standard PDE5 inhibitor tadalafil increases its therapeutic efficacy in pulmonary hypertensive rats that were deficient in vitamin D., This study was supported by grants from Ministerio de Economía y Competitividad (PID2019-107363RB-I00 and PID2020-117939RB-I00), Fundación Contra la Hipertensión Pulmonar (FCHP, Empathy study) and Sociedad Española de Neumología y Cirugía Torácica (SEPAR, 1204/2022). R.A. is funded by the EC Horizon 2020 Marie Skłodowska-Curie grant (No. 847635), and acknowledges Fundação para a Ciência e a Technologia (FCT) under the auspices of the project RELAX-2-PAH (2022.08921.PTDC; https://doi.org/10.54499/2022.08921.PTDC). M.A.O. is funded by Universidad Complutense/Banco Santander CT63/19-CT64/19.